Cargando…

Debate: Does it matter how you lower blood pressure?

Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly h...

Descripción completa

Detalles Bibliográficos
Autor principal: Alderman, Michael H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59601/
https://www.ncbi.nlm.nih.gov/pubmed/11714412
http://dx.doi.org/10.1186/cvm-1-2-069
_version_ 1782120082545049600
author Alderman, Michael H
author_facet Alderman, Michael H
author_sort Alderman, Michael H
collection PubMed
description Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly half that expected. This suggested that adverse drug effects of diuretics and β-blockers might have detracted from their hypotensive effects. Trials with newer antihypertensive classes have revealed superior effects on outcomes associated with converting enzyme inhibitor use, and that α-blockers are less cardioprotective than diuretics. These studies establish that simple blood pressure reduction is an inadequate guide to therapy. The challenge now will be to determine the optimal therapy for each hypertensive patient.
format Text
id pubmed-59601
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-596012001-11-06 Debate: Does it matter how you lower blood pressure? Alderman, Michael H Curr Control Trials Cardiovasc Med Commentary Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly half that expected. This suggested that adverse drug effects of diuretics and β-blockers might have detracted from their hypotensive effects. Trials with newer antihypertensive classes have revealed superior effects on outcomes associated with converting enzyme inhibitor use, and that α-blockers are less cardioprotective than diuretics. These studies establish that simple blood pressure reduction is an inadequate guide to therapy. The challenge now will be to determine the optimal therapy for each hypertensive patient. BioMed Central 2000 2000-08-17 /pmc/articles/PMC59601/ /pubmed/11714412 http://dx.doi.org/10.1186/cvm-1-2-069 Text en Copyright © 2000 Current Controlled Trials Ltd
spellingShingle Commentary
Alderman, Michael H
Debate: Does it matter how you lower blood pressure?
title Debate: Does it matter how you lower blood pressure?
title_full Debate: Does it matter how you lower blood pressure?
title_fullStr Debate: Does it matter how you lower blood pressure?
title_full_unstemmed Debate: Does it matter how you lower blood pressure?
title_short Debate: Does it matter how you lower blood pressure?
title_sort debate: does it matter how you lower blood pressure?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59601/
https://www.ncbi.nlm.nih.gov/pubmed/11714412
http://dx.doi.org/10.1186/cvm-1-2-069
work_keys_str_mv AT aldermanmichaelh debatedoesitmatterhowyoulowerbloodpressure